Login to Your Account

Financings Roundup

Regulus Therapeutics to Raise $42.8M in a Public Offering

By Catherine Shaffer
Staff Writer

Thursday, July 18, 2013
A new public offering of 4.5 million shares of common stock at $9.50 per share will help to float Regulus Therapeutics Inc.'s pipeline of drugs targeting microRNAs, including its lead compound RG-101 for hepatitis C virus. The offering is expected to raise gross proceeds of $42.8 million, and will close on or about July 22.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription